It’s summertime, and given the scrutiny and strain the profession has been under these past several months, I suspect all of you are ready for a reprieve from the limelight.
A California lawsuit claims that manufacturers, distributors and sellers of fish oil supplements failed to give clear reasonable warnings that consumers are being exposed to unacceptably high levels of polychlorinated biphenyls, which are known carcinogens and teratogens.
Actemra: first IL-6 receptor inhibitor for RA; BuTrans: first once-weekly transdermal opioid; Onsolis: opioid buccal film for breakthrough cancer pain; Victoza: first GLP-1 analogue for type 2 diabetes